C12N 2760/18432
Use of virus as therapeutic agent, other than vaccine
Official title: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N2760/18432 (Use of virus as therapeutic agent, other than vaccine) appears on 23 US grants and 38 published applications in this corpus.
Search patents in C12N- Granted patents
- 23
- Published applications
- 38
- Assignees
- 27
- Inventors
- 68
- Latest grant
- 16 Sep 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2005 | 0 | 1 |
| 2006 | 1 | 0 |
| 2007 | 0 | 1 |
| 2008 | 1 | 0 |
| 2009 | 1 | 1 |
| 2010 | 2 | 2 |
| 2011 | 0 | 2 |
| 2012 | 0 | 0 |
| 2013 | 0 | 2 |
| 2014 | 0 | 2 |
| 2015 | 1 | 3 |
| 2016 | 2 | 1 |
| 2017 | 2 | 3 |
| 2018 | 2 | 4 |
| 2019 | 3 | 4 |
| 2020 | 1 | 2 |
| 2021 | 2 | 1 |
| 2022 | 2 | 1 |
| 2023 | 0 | 3 |
| 2024 | 1 | 2 |
| 2025 | 2 | 2 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Materials and methods for treating cancer16 Sep 2025US 12,414,974 B2Mayo Foundation for Medical Education and Research
- RNA viruses for immunovirotherapy20 May 2025US 12,303,540 B2Deutsches Krebsforschung-Szentrum, Ruprecht-Karls-Universitat Heidelberg
- Materials and methods for treating cancer9 Jan 2024US 11,865,150 B2Mayo Foundation for Medical Education and Research
- DNA molecules producing custom designed replicating and non-replicating negative stranded RNA viruses and uses there of27 Dec 2022US 11,535,864 B2
- Multiple viral antigen COVID vaccine and therapeutic8 Nov 2022US 11,491,197 B2
- Neddylation-activating enzyme inhibitors as viral sensitizers and uses thereof15 Jan 2026US 2026/0015592 A1Ottawa Hospital Research Institute
- Novel usage of oncolytic gene-modified measles virus19 Jun 2025US 2025/0195634 A1The University of Tokyo
- Genetically modified ungulate cells and their uses in cancer therapy23 Jan 2025US 2025/0025501 A1Fios Therapeutics LLC
- Materials and methods for treating cancer23 May 2024US 2024/0165178 A1Mayo Foundation for Medical Education and Research
- Or2l13 agonists to treat cvd with dysregulated platelet activation4 Apr 2024US 2024/0108591 A1The Cleveland Clinic Foundation
Most cited
By later US patents
- Method for limiting the growth of cancer cells using an attenuated measles virus25US 7,118,740 B1Mayo Foundation for Medical Education and Research · 2006
- Degron fusion constructs and methods for controlling protein production3US 10,550,379 B2The Board of Trustees of the Leland Stanford Junior University · 2020
- Method for limiting the growth of cancer cells using an attenuated measles virus3US 7,393,527 B2Mayo Foundation for Medical Education and Research · 2008
- Method for limiting the growth of cancer cells using an attenuated measles virus3US 7,670,598 B2Mayo Foundation for Medical Education and Research · 2010
- PVRL4 (Nectin4) is a receptor for measles virus3US 9,399,062 B22016